[MyD88 L265P mutation and B cell tumor].

Myeloid differentiation factor (MyD88) is an important adaptor protein mediating the signal transduction of most Toll-like receptors (TLR), interleukin-1 receptor (IL-1R) and interleukin-18 receptor (IL-18R) that play a key role to mediate innate immune response. Recently, activating of MYD88 L265 mutation has been reported in about of 90% lymphoplasmacytoid lymphoma/Waldenström's Macroglobulinemia, about of 29% activated type diffuse large B-cell lymphoma and other subtypes of B cell tumors demonstrating the MyD88 signaling plays an important role in B cell tumorigenesis, and inhibitors targeting MyD88 might become a new remedy for B cell tumors. In this review, the latest advances in the roles of MyD88 L265P mutation in B cell tumorigenesis were summarized.